Strong IPO Performance from Biotech Firms
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Should l Buy PSUS?
Source: renaissancecapital
- Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
- Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
- Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
- Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSUS
Wall Street analysts forecast PSUS stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 42.710
Low
Averages
High
Current: 42.710
Low
Averages
High
No data
About PSUS
Pershing Square USA, Ltd. (the Fund) is a non-diversified, closed-end investment company. It is designed primarily for long-term investors and is not intended to be a trading vehicle. The Fund's investment objective is to preserve capital and seek maximum, long-term capital appreciation commensurate with reasonable risk. The Fund shall seek to achieve its investment objective by investing principally in common stocks that Pershing Square Capital Management, L.P., a Delaware limited partnership (the Adviser), believes exhibit significant valuation discrepancies between current trading prices and intrinsic business (or net asset) value, often with a catalyst for value recognition. The Adviser expects that the substantial majority of the Fund's investment portfolio shall be invested in 12 to 15 core long-term holdings in large-capitalization, investment grade, free-cash-flow-generative North American durable growth companies. The Fund has no operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bill Ackman's Investments Boost PS Stock Price
- Stock Price Surge: Bill Ackman's personal investments propelled Pershing Square (PS) stock to a 36% increase on Friday, followed by a 6% rise in after-hours trading, despite still trading below the $50 listing price, indicating a recovery in market confidence towards his investments.
- Incentive Measures: The IPO featured a 'sweetener' where investors received an additional share of the management company for every five shares of the closed-end fund purchased, which, while still resulting in approximately a 3% loss for investors, aimed to attract more retail participation in the offering.
- Focus on Retail Investors: Ackman stated in an interview that PS's listing favored retail investors over institutional ones, and despite facing criticism for the fund's poor performance, he emphasized his commitment to supporting retail allocations, reflecting a strategic shift in market engagement.
- Optimistic Market Sentiment: Investor sentiment on Stocktwits was extremely bullish with high trading volumes, with some users even suggesting that PS could become the next 'Berkshire Hathaway', showcasing strong trust and expectations in Ackman's asset management capabilities.
See More
Strong IPO Performance from Biotech Firms
- Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
- Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
- Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
- Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
See More
Ackman Blames Retail Investors for Pershing Square Stock Drop
- IPO Price Fluctuation: Pershing Square USA (PSUS) debuted at an IPO price of $50 per share but opened approximately 18% lower at $41 on Wednesday, indicating a lack of market confidence that could hinder future fundraising efforts.
- Retail Investor Behavior: Ackman criticized retail investors for overcommitting during the IPO, leading to forced sell-offs due to insufficient cash, which not only impacted stock prices but could also harm the company's long-term reputation.
- Institutional Investor Dominance: Ackman noted that over 80% of the capital came from institutional investors, highlighting that despite significant retail participation, institutional backing remains crucial, reflecting market confidence in the fund.
- Future Fund Plans: During a conference call in Montreal, Ackman indicated he might launch another fund within a year or even before the end of 2026, demonstrating his long-term optimism for the market despite current challenges.
See More
Pershing Square's IPO Performance Falls Short
- IPO Performance: Pershing Square USA and Pershing Square Inc. debuted on the NYSE on Wednesday, with PSUS closing at $43.76, approximately 12% lower than its IPO price of $50, indicating market concerns about its initial performance.
- Ackman's Investment: Founder Bill Ackman disclosed that he purchased 500,000 shares of PSUS and 800,000 shares of PS in the open market post-debut, with a combined estimated value exceeding $40 million, reflecting his confidence in the company's future.
- Retail Investor Sentiment: On Stocktwits, retail sentiment for PSUS stock climbed from 'bullish' to 'extremely bullish' within 24 hours, while PS stock sentiment slipped from 'extremely bullish' to 'bullish', showcasing differing market perceptions of the two stocks.
- Ackman's Clarification: Ackman clarified that he did not blame retail investors for the price drop, explaining that the late start to trading likely led to rapid sell-offs by investors allocated more shares than desired, which may have impacted stock performance.
See More
Pershing Square to Host Public Event on IPOs
- Event Timing: Pershing Square Inc. will host a public X Spaces event on May 1, 2026, at 9:00 AM ET, where CEO Bill Ackman and CIO Ryan Israel will discuss the recently completed IPOs of PS and PSUS, aiming to enhance investor transparency and trust.
- Interactive Engagement: The event will be open to the public, allowing participants to ask questions directly to Bill and Ryan, fostering interaction with investors and strengthening the relationship between the company and its shareholders, thereby enhancing brand image.
- Company Background: Pershing Square Inc. is the parent company of Pershing Square Capital Management, L.P., an SEC-registered investment advisor focused on investment funds and other companies, based in New York City, showcasing its expertise and influence in the financial services industry.
- Registration Information: The event will be conducted via the X platform, with participants able to access it through the link https://x.com/BillAckman, ensuring broad dissemination of information and participation, further enhancing the company's market visibility.
See More
PSH to Benefit from Reduction of Performance Fees
- Successful IPO Completion: The initial public offering of Pershing Square USA, Ltd. was successfully completed, raising a total of $5 billion, which will directly benefit PSH and its shareholders, enhancing its competitive position in the market.
- Reduction in Performance Fees: Under the amended Investment Management Agreement from 2024, PSH's performance fees will be reduced by 20%, meaning PSH will achieve higher net earnings from management fees, thereby enhancing long-term return potential.
- Management Company Platform Potential: The successful listing of Pershing Square Inc. lays the groundwork for future new fund launches, with Bill Ackman stating that this will further drive down PSH's performance fees, boosting investor confidence.
- Growth in Assets Under Management: As Pershing Square's assets under management continue to grow, PSH will benefit from the new performance fee offset mechanism, which is expected to significantly enhance its long-term investment returns and increase shareholder value.
See More
Bill Ackman's Investments Boost PS Stock Price
- Stock Price Surge: Bill Ackman's personal investments propelled Pershing Square (PS) stock to a 36% increase on Friday, followed by a 6% rise in after-hours trading, despite still trading below the $50 listing price, indicating a recovery in market confidence towards his investments.
- Incentive Measures: The IPO featured a 'sweetener' where investors received an additional share of the management company for every five shares of the closed-end fund purchased, which, while still resulting in approximately a 3% loss for investors, aimed to attract more retail participation in the offering.
- Focus on Retail Investors: Ackman stated in an interview that PS's listing favored retail investors over institutional ones, and despite facing criticism for the fund's poor performance, he emphasized his commitment to supporting retail allocations, reflecting a strategic shift in market engagement.
- Optimistic Market Sentiment: Investor sentiment on Stocktwits was extremely bullish with high trading volumes, with some users even suggesting that PS could become the next 'Berkshire Hathaway', showcasing strong trust and expectations in Ackman's asset management capabilities.
See More
Strong IPO Performance from Biotech Firms
- Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
- Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
- Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
- Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
See More
Ackman Blames Retail Investors for Pershing Square Stock Drop
- IPO Price Fluctuation: Pershing Square USA (PSUS) debuted at an IPO price of $50 per share but opened approximately 18% lower at $41 on Wednesday, indicating a lack of market confidence that could hinder future fundraising efforts.
- Retail Investor Behavior: Ackman criticized retail investors for overcommitting during the IPO, leading to forced sell-offs due to insufficient cash, which not only impacted stock prices but could also harm the company's long-term reputation.
- Institutional Investor Dominance: Ackman noted that over 80% of the capital came from institutional investors, highlighting that despite significant retail participation, institutional backing remains crucial, reflecting market confidence in the fund.
- Future Fund Plans: During a conference call in Montreal, Ackman indicated he might launch another fund within a year or even before the end of 2026, demonstrating his long-term optimism for the market despite current challenges.
See More
Pershing Square's IPO Performance Falls Short
- IPO Performance: Pershing Square USA and Pershing Square Inc. debuted on the NYSE on Wednesday, with PSUS closing at $43.76, approximately 12% lower than its IPO price of $50, indicating market concerns about its initial performance.
- Ackman's Investment: Founder Bill Ackman disclosed that he purchased 500,000 shares of PSUS and 800,000 shares of PS in the open market post-debut, with a combined estimated value exceeding $40 million, reflecting his confidence in the company's future.
- Retail Investor Sentiment: On Stocktwits, retail sentiment for PSUS stock climbed from 'bullish' to 'extremely bullish' within 24 hours, while PS stock sentiment slipped from 'extremely bullish' to 'bullish', showcasing differing market perceptions of the two stocks.
- Ackman's Clarification: Ackman clarified that he did not blame retail investors for the price drop, explaining that the late start to trading likely led to rapid sell-offs by investors allocated more shares than desired, which may have impacted stock performance.
See More
Pershing Square to Host Public Event on IPOs
- Event Timing: Pershing Square Inc. will host a public X Spaces event on May 1, 2026, at 9:00 AM ET, where CEO Bill Ackman and CIO Ryan Israel will discuss the recently completed IPOs of PS and PSUS, aiming to enhance investor transparency and trust.
- Interactive Engagement: The event will be open to the public, allowing participants to ask questions directly to Bill and Ryan, fostering interaction with investors and strengthening the relationship between the company and its shareholders, thereby enhancing brand image.
- Company Background: Pershing Square Inc. is the parent company of Pershing Square Capital Management, L.P., an SEC-registered investment advisor focused on investment funds and other companies, based in New York City, showcasing its expertise and influence in the financial services industry.
- Registration Information: The event will be conducted via the X platform, with participants able to access it through the link https://x.com/BillAckman, ensuring broad dissemination of information and participation, further enhancing the company's market visibility.
See More
PSH to Benefit from Reduction of Performance Fees
- Successful IPO Completion: The initial public offering of Pershing Square USA, Ltd. was successfully completed, raising a total of $5 billion, which will directly benefit PSH and its shareholders, enhancing its competitive position in the market.
- Reduction in Performance Fees: Under the amended Investment Management Agreement from 2024, PSH's performance fees will be reduced by 20%, meaning PSH will achieve higher net earnings from management fees, thereby enhancing long-term return potential.
- Management Company Platform Potential: The successful listing of Pershing Square Inc. lays the groundwork for future new fund launches, with Bill Ackman stating that this will further drive down PSH's performance fees, boosting investor confidence.
- Growth in Assets Under Management: As Pershing Square's assets under management continue to grow, PSH will benefit from the new performance fee offset mechanism, which is expected to significantly enhance its long-term investment returns and increase shareholder value.
See More
